GE Healthcare is preparing for its spinoff from GE, which is planned for the first week of January. The company’s split will allow it to operate under a new board, as well as manage its own capital. That capital will be primarily invested in acquisitions and research and development efforts, according to GE Healthcare's CEO for the U.S. and Canada.
The initiative, slated to be completed by the first half of 2021, is being undertaken after an unsuccessful effort to sell the division to a willing acquirer
Health systems have spent billions on portals while investments in modernizing the voice channel — the dominant preference of healthcare consumers — have taken a backseat.
The seed round for MDmetrix, which was founded in 2016, was led by Founders Co-op, and Arnold Venture Group and WRF Capital participated.
As part of the partnership, the Mount Sinai spinout OOVA's tool will be available to more than 3 million potential customers and 35,000 clinicians through bundled sales with Thorne supplements.
In a deal expected to close by the end of this year, Premier will scoop up Stanson Health, a Cedars-Sinai Medical Center spinout that was founded in 2013.
With $2 million in seed funding, the company, First Mile Care, is utilizing a coaching and support model in an effort to reverse prediabetes.
PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies.
GE Ventures has been incubating Drawbridge Health for two years. With its pain-free blood draw device, the business seeks to increase patient compliance and simplify the diagnostic workflow.
Seattle-based Xealth, a new startup out of Providence Health & Services, has nabbed $8.5 million in a round led by DFJ. The company's platform lets physicians prescribe digital health content, apps and services.
Mount Sinai Health System's new spinout company, Sema4, will rely on genomic and clinical data to better diagnose, treat and prevent diseases.
IsoPlexis, a Yale spinout developing an immunologic assay that helps researchers understand how therapies impact individual patients on a cellular level, seems to have raised a nice chunk of startup capital. The company, formed last year by a couple of MBA candidates, has raised $1.3 million of a $1.7 million early-stage round, according to a […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.